Overview
The combination of lactoferrin + L. rhamnosus GG (LGG) ranked SUCRA 95.7% for lowest NEC rate in a network meta-analysis of 27 RCTs (n=9,501). This intervention exemplifies multiple Karen's Brain primitives operating synergistically.
Mechanism
- Lactoferrin (Primitives 2, 8): Sequesters free iron in the intestinal lumen, starving Enterobacteriaceae of the metal required for siderophore-mediated iron acquisition and growth. This recapitulates the host's nutritional immunity strategy.
- LGG (Primitive 5): Restores Bifidobacterium-dominant colonization pattern appropriate for neonatal gut; competitively excludes pathogenic Enterobacteriaceae
- Synergy (Primitive 4): Lactoferrin disables the iron-dependent Achilles' heel of pathogens while LGG fills the ecological niche with beneficial taxa
Clinical Evidence
Network meta-analysis (27 RCTs, n=9,501): Lactoferrin + LGG combination achieved the highest SUCRA ranking (95.7%) for NEC prevention among all evaluated interventions, outperforming either agent alone.
Clinical Considerations
- Bovine lactoferrin is the most commonly studied form
- Dosing protocols vary across studies; most use 100-200 mg/day lactoferrin
- Applicable to preterm infants at highest NEC risk (VLBW, <32 weeks)
- Compatible with breast milk feeding (breast milk naturally contains both lactoferrin and promotes Bifidobacterium)